News >

Immunotherapy Biomarker Hunt Continues in Lung Cancer

Ellie Leick
Published: Wednesday, Sep 11, 2019

Robert A. Kratzke, MD, professor of medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota

Robert A. Kratzke, MD

Biomarkers continue to be an area of active research to determine which patient populations of lung cancer will garner the best response to immunotherapy, either as single agents or in combination, as well as the surge of molecularly driven therapies that have become available in recent years, explained Robert A. Kratzke, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x